CBIO

Crescent Biopharma
CBIO

Overview Fund Trends Analyst Outlook Journalist POV

78 hedge funds and large institutions have $110M invested in Crescent Biopharma in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 25 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

less ownership

Funds ownership: →

less funds holding

Funds holding: →

less capital invested

Capital invested by funds: $ → $

28% less call options, than puts

Call options by funds: $594K | Put options by funds: $826K

58% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 19

Holders
78
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$594K
Puts
$826K
Net Calls
Net Calls Change

Top Buyers

1
+$2.51M
2
+$2.01M
3
+$1.07M
4
AQR Capital Management
AQR Capital Management
Connecticut
+$638K
5
BlackRock
BlackRock
New York
+$623K

Top Sellers

1
-$8.27M
2
-$3.38M
3
-$1.88M
4
Morgan Stanley
Morgan Stanley
New York
-$1.04M
5
Millennium Management
Millennium Management
New York
-$519K
Name Holding Trade Value Shares
Change 		Change in
Stake
76
$65
77
–
78
–
79
–
80
–
81
–
82
–
83
–
84
–
85
–
86
–
87
–
88
–
89
–
90
–
91
–
92
–
93
–
94
–
95
–
96
–
1 2 3
4